Search the Newsreel

Income Investors Should Know That Jardine Matheson Holdings Limited (SGX:J36) Goes Ex-Dividend Soon

Brian Dyson Obituary (1935 - 2026) - Atlanta, GA - Atlanta Journal-Constitution

Brian Dyson, former Vice Chairman and COO of The Coca-Cola Company, passed away at 90 on August 9, 2026. Born in Argentina, Dyson had a distinguished career with Coca-Cola, led several entrepreneurial ventures, and was known for his athletic pursuits and writing. He is …

ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints

How Rapport Therapeutics Inc. (RAPP) Affects Rotational Strategy Timing

This article analyzes Rapport Therapeutics Inc. (RAPP) using AI models to determine its effect on rotational strategy timing. Key findings suggest a strong sentiment supporting an overweight bias, with resistance being tested. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, …

Straits Trading (SGX:S20) Stock Trails Revenue Growth As Losses Persist

Coca-Cola (KO) Lifted Its Guidance, Is The Stock Fully Priced?

What Does Lantheus Holdings (LNTH) FDA Approval Mean For Its Alzheimer’s Push?

Lantheus Holdings received FDA approval for TAUKLARIFY, a tau PET imaging agent for Alzheimer's disease diagnostics, expanding its molecular imaging portfolio beyond prostate cancer. This approval strengthens Lantheus's position in the Alzheimer's imaging market and supports its strategy of diversifying revenue and meeting the …

AdaptHealth Corp. Data Breach: Edelson Lechtzin LLP Launches Investigation Into Exposure of Personal Information

Edelson Lechtzin LLP, a national class action law firm, is investigating a data breach at AdaptHealth Corp. that exposed patient data. The breach, disclosed on July 2, 2026, involved a social engineering attack that compromised a third-party contractor's credentials, leading to unauthorized access to …

Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates

Vivos Therapeutics, Inc. (VVOS) reported a Q2 loss of $0.31 per share, which was better than the Zacks Consensus Estimate of a $0.42 loss. However, the company missed revenue estimates, posting $5.15 million against an expected $5.43 million. Despite beating EPS estimates two out …

How TG Therapeutics’ Q2 2026 Revenue Surge And Higher Guidance At TG Therapeutics (TGTX) Has Changed Its Investment Story

US Physical Therapy Appoints New Executive Vice President CFO

Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker

An insider at Zevra Therapeutics (ZVRA) has filed a Form 144 notice to resell up to 42,666 common shares. These shares are linked to restricted stock units granted in June 2025 and are planned for potential sale on NASDAQ. The filing also references previous …

Colonial Motor (NZSE:CMO) Stock Looks Cheap, But Earnings Quality Remains Fragile

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat

ALGS Stock Rallies 16% After-Hours On $25M Cash Boost From China Hepatitis B Drug Deal

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC

This article provides current stock price information for First Tracks Biotherapeutics, Inc. (TRAX) on MEXC, detailing its live price, market data, and recent performance. It also includes instructions on how to buy TRAX on MEXC and offers a company overview, including its focus on …

Iovance Biotherapeutics, Inc. stock Analysis: 130% Rally & Overbought Signals 2026

Iovance Biotherapeutics, Inc. stock has rallied over 130% in 2026, closing at $6.98, but is showing strong overbought signals across multiple timeframes with daily RSI at 73.02. While the daily trend remains bullish due to strong EMA alignment and positive MACD, the elevated RSI …

Iovance Biotherapeutics, Inc. stock jumps 130% in 2026 but RSI screams overbought

Travelers Companies (TRV) Adds Anthony Jabbour To Its Board

Travelers Companies (TRV) has appointed Anthony Jabbour, former CEO of Dun & Bradstreet Holdings and Black Knight, to its Board of Directors. Jabbour will serve on the Audit Committee and Risk Committee, bringing extensive experience from financial services and technology. This appointment reinforces Travelers' …

Top Magnum Ice Cream (MICC) Competitors 2026

TMC The Metals (TMC) Has Investors Watching, What Is Behind The Fresh Attention?

TMC The Metals (TMC) is gaining investor attention due to progress on U.S. seabed mining permits and advancements in its offshore collection system. Despite a recent 7-day share price return of 7.04%, the year-to-date performance shows a decline of 34.96%. The company's fair value …

First Bancorp (FBNC) Could Be 30% Below Fair Value Following Its Revenue Beat

Should Coca-Cola Consolidated’s Higher Sales but Lower Profit Require Action From Coca-Cola Consolidated (COKE) Investors?

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Bank of the James president buys $2,705 in company stock

Michael A. Syrek, President of Bank of the James, recently purchased 100 shares of the company's common stock for $27.05 per share, totaling $2,705. This transaction, occurring on August 7, 2026, was reported earlier than legally required. The purchase follows a 100% return on …

BofA Securities Maintains Aardvark Therapeutics(AARD.US) With Sell Rating

BofA Securities has reiterated its Sell rating on Aardvark Therapeutics (AARD.US). The article does not provide further details regarding the financial implications or the analyst's rationale for maintaining this rating.

Corcept therapeutics chief development officer sells $1.8m in stock

William Guyer, Chief Development Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), sold shares worth approximately $1.85 million on August 10, 2026, through two separate transactions under a 10b5-1 plan. Despite the sales, which occurred while the stock was near its 52-week high, Guyer also acquired …

Is Iovance Biotherapeutics (IOVA) Undervalued As Q2 Earnings Reaffirm Revenue Guidance?

Diluted earnings per share (diluted EPS) of Spero Therapeutics, Inc. – BMV:SPRO

Bill Gates’ Portfolio Just Added Home Depot (HD) Despite Risks. Time to Buy?

Latest filings show the Bill & Melinda Gates Foundation Trust opened a new position in Home Depot (NYSE:HD), worth about $353 million, during the second quarter. The stock is down about 15% over the past year. What's plaguing HD? High mortgage rates and inflation …

Relmada (RLMD) Q2 2026 Earnings Call Transcript

BMO Capital Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $20

BMO Capital has initiated coverage on MapLight Therapeutics (MPLT.US) with a Buy rating and set a price target of $20. This indicates a positive outlook from the investment firm regarding the company's future stock performance.

Avalo Therapeutics CMO Mittie Doyle sells $13,580 in stock

Mittie Doyle, CMO at Avalo Therapeutics (NASDAQ:AVTX), sold 679 shares for $13,580 after exercising stock options under a Rule 10b5-1 trading plan. Following these transactions, she directly holds 51,776 shares and 114,413 stock options. This news follows Avalo's inclusion in the Russell 2000 and …

Notable trades: Netflix, Coca-Cola, Pfizer among notable names

Insider transactions were seen across major firms this week, including Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]), Merck (MRK [https://seekingalpha.com/symbol/MRK]), and Pfizer (PFE [https://seekingalpha.com/symbol/PFE]). The following trades took place between August 10 and August 14. * Netflix (NFLX [https://seekingalpha.com/symbol/NFLX]) Chief Financial Officer Spencer Neumann sold 9,248 shares at …

MOS Stock Hits Over 5-Year Lows – Why Did Mosaic Withdraw Its Phosphate Production Guidance For 2026?